Abbisko Cayman Ltd
HKEX:2256

Watchlist Manager
Abbisko Cayman Ltd Logo
Abbisko Cayman Ltd
HKEX:2256
Watchlist
Price: 13.23 HKD -2.22%
Market Cap: 8.9B HKD
Section:
 

Relative Value

The Relative Value of one Abbisko Cayman Ltd stock under the Base Case scenario is 5.44 HKD. Compared to the current market price of 13.23 HKD, Abbisko Cayman Ltd is Overvalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
5.44 HKD
Overvaluation 59%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

13.6
P/S
P/S
Price to Sales
13.6
vs History
53
vs Industry
43
Median 3Y
12.3
Median 5Y
16.5
Industry
7.9
Forward
12.7
More Details
56
P/E
P/E
Price to Earnings
56
vs History
19
vs Industry
Median 3Y
-3.6
Median 5Y
-3.4
Industry
23.7
Forward
95.9
More Details
65.1
P/OCF
P/OCF
Price to OCF
65.1
vs History
7
vs Industry
Median 3Y
-5.3
Median 5Y
-7.2
Industry
22
More Details
37.5
P/FCFE
P/FCFE
Price to FCFE
37.5
vs History
7
vs Industry
Median 3Y
-4.8
Median 5Y
-4.9
Industry
23.8
More Details
3.9
P/B
P/B
Price to Book Value
3.9
vs History
7
vs Industry
37
Median 3Y
1
Median 5Y
1
Industry
3.3
More Details
10.2
EV/S
EV/S
Enterprise Value to Sales
10.2
vs History
19
vs Industry
46
Median 3Y
0.7
Median 5Y
-0.1
Industry
8.3
Forward
9.5
More Details
10.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.2
vs History
19
vs Industry
52
Median 3Y
0.7
Median 5Y
-0.1
Industry
10.1
More Details
50
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
50
vs History
23
vs Industry
13
Median 3Y
0.9
Median 5Y
0.5
Industry
6.4
Forward
73.6
More Details
62.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
62.4
vs History
7
vs Industry
11
Median 3Y
0.6
Median 5Y
0.1
Industry
7
Forward
80.2
More Details
48.8
EV/OCF
EV/OCF
Enterprise Value to OCF
48.8
vs History
7
vs Industry
15
Median 3Y
0.8
Median 5Y
0.6
Industry
8.3
More Details
50.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
50.8
vs History
7
vs Industry
11
Median 3Y
0.8
Median 5Y
0.5
Industry
6.5
More Details
46.7
EV/IC
EV/IC
Enterprise Value to IC
46.7
vs History
11
vs Industry
11
Median 3Y
0.8
Median 5Y
0.2
Industry
5.7
More Details

Multiples Across Competitors

Competitors Multiples
Abbisko Cayman Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Abbisko Cayman Ltd
HKEX:2256
9.3B HKD 13.6 56 50 62.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 837 682.7 -160 825.5 -195 293.4 -193 064.9
US
Abbvie Inc
NYSE:ABBV
393.8B USD 6.6 167.7 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
174.5B USD 4.9 24.9 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
150.9B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD 9.7 30.9 22.7 23.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 082 -531.3 -578.5 -563.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD 5.5 17.2 16.4 18.6
AU
CSL Ltd
ASX:CSL
84.7B AUD 3.6 18.7 12.6 15.7
NL
argenx SE
XBRU:ARGX
44.5B EUR 14.5 34.1 58.7 60.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.2B USD 16.3 1 198.1 157.3 190.8
P/E Multiple
Earnings Growth PEG
CN
Abbisko Cayman Ltd
HKEX:2256
Average P/E: 174
56
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 825.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.9
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
NL
argenx SE
XBRU:ARGX
34.1
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 198.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Abbisko Cayman Ltd
HKEX:2256
Average EV/EBITDA: 40.5
50
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 293.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
NL
argenx SE
XBRU:ARGX
58.7
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
157.3
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Abbisko Cayman Ltd
HKEX:2256
Average EV/EBIT: 47.2
62.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 064.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.7
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
NL
argenx SE
XBRU:ARGX
60.4
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
190.8
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.